AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

Akeso’s EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate

SK pens $315M pact with fellow South Korean company for Parkinson’s prospect

Acelot Announces Initiation of Dosing in Phase Ia Clinical Trial of ACE-2223, a First-in-Class Oral Small Molecule Targeting Aggregated TDP-43 in Amyotrophic Lateral Sclerosis (ALS)

Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement